Profile data is unavailable for this security.
About the company
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS) and the manufacture and supply of marketable molecules such as specialty chemicals, vitamins and chemicals, and disinfectants. Its segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. The Marketable Molecules segment manufactures and supplies intermediates, quaternary compounds, specialty chemicals, and various products for pharmaceuticals and cosmetics. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom, and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., and others.
- Revenue in INR (TTM)27.12bn
- Net income in INR32.40m
- Incorporated2007
- Employees1.13k
- LocationDishman Carbogen Amcis LtdDishman Corporate HouseIscon-Bopal Road, AmbliAHMEDABAD 380058IndiaIND
- Phone+91 2 717420100
- Fax+91 7 926420198
- Websitehttps://www.carbogen-amcis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Senores Pharmaceuticals Ltd | -100.00bn | -100.00bn | 26.17bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 85.64 | -- | 86.17 | -- | -- | -- |
| Gujarat Themis Biosyn Ltd | 1.51bn | 487.73m | 26.34bn | 160.00 | 78.15 | 15.34 | 48.65 | 17.47 | 4.47 | 4.47 | 13.83 | 22.79 | 0.5773 | 13.98 | 5.18 | -- | 18.67 | 30.70 | 20.08 | 34.37 | 61.20 | 68.03 | 32.34 | 35.51 | 2.28 | 174.42 | 0.1093 | -- | -11.20 | 12.12 | -17.56 | 15.55 | 104.61 | 24.95 |
| Solara Active Pharma Sciences Ltd | 12.84bn | 5.40m | 27.76bn | 2.16k | -- | 2.71 | 27.82 | 2.16 | -0.1753 | -0.1753 | 375.11 | 227.72 | 0.5603 | 1.85 | 3.80 | -- | 0.0236 | -3.27 | 0.0452 | -5.35 | 51.21 | 41.54 | 0.0421 | -6.17 | 0.4352 | 0.9322 | 0.4205 | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
| Indoco Remedies Ltd | 16.65bn | -737.30m | 27.81bn | 5.93k | -- | 2.72 | 77.43 | 1.67 | -8.45 | -8.45 | 168.75 | 110.79 | 0.7279 | 1.29 | 4.39 | -- | -3.41 | 4.84 | -4.94 | 6.87 | 70.08 | 66.53 | -4.68 | 5.16 | 0.7203 | -0.22 | 0.4938 | 15.44 | -8.38 | 8.51 | -174.89 | -- | 43.53 | -7.79 |
| IOL Chemicals and Pharmaceuticals Ltd | 20.79bn | 1.01bn | 28.62bn | 2.78k | 28.31 | 1.70 | 16.54 | 1.38 | 3.44 | 3.44 | 70.85 | 57.50 | 0.8988 | 3.54 | 4.22 | -- | 4.37 | 10.26 | 5.85 | 13.42 | 33.06 | 32.77 | 4.86 | 9.33 | 1.30 | 8.83 | 0.0649 | -- | -2.51 | 1.88 | -24.82 | -22.49 | 21.61 | -- |
| Zota Health Care Ltd | 2.93bn | -563.98m | 29.30bn | 445.00 | -- | 12.60 | -- | 10.00 | -20.74 | -20.74 | 107.84 | 78.12 | 0.8779 | 1.72 | 8.65 | -- | -17.00 | -7.79 | -23.17 | -10.57 | 53.13 | 42.76 | -19.37 | -8.01 | 0.78 | -4.54 | 0.3806 | -- | 62.32 | 25.23 | -293.08 | -- | 49.40 | 0.00 |
| Morepen Laboratories Ltd | 18.12bn | 1.18bn | 34.39bn | 1.62k | 28.53 | 2.97 | 23.39 | 1.90 | 2.20 | 2.20 | 33.38 | 21.10 | 1.18 | 4.23 | 5.56 | -- | 7.69 | 8.14 | 11.04 | 12.81 | 36.01 | 33.88 | 6.51 | 5.91 | 1.72 | 17.39 | 0.0813 | -- | 7.17 | 16.26 | 22.73 | 28.58 | 65.86 | -- |
| Gufic BioSciences Ltd | 8.20bn | 696.49m | 35.01bn | 1.45k | 50.24 | 5.82 | 38.60 | 4.27 | 6.95 | 6.95 | 81.80 | 59.94 | 0.7249 | 1.80 | 2.54 | -- | 6.16 | 10.27 | 9.27 | 16.11 | 54.29 | 47.54 | 8.50 | 10.48 | 1.05 | 4.92 | 0.3587 | -- | 1.63 | 16.69 | -19.14 | 25.15 | 13.64 | 14.87 |
| Orchid Pharma Ltd | 9.22bn | 996.57m | 35.88bn | 872.00 | 35.98 | 2.83 | 27.53 | 3.89 | 19.66 | 19.66 | 181.88 | 249.86 | 0.5688 | 1.84 | 4.22 | -- | 5.91 | 1.40 | 7.10 | 1.72 | 40.97 | 38.36 | 10.39 | 2.75 | 1.68 | 5.68 | 0.1211 | -- | 12.52 | 13.76 | 8.13 | -- | 104.06 | -- |
| Dishman Carbogen Amcis Ltd | 27.12bn | 32.40m | 38.73bn | 1.13k | 1,176.19 | 0.6641 | 13.04 | 1.43 | 0.21 | 0.21 | 173.66 | 371.95 | 0.277 | 0.5627 | 4.82 | -- | 0.0331 | -0.7247 | 0.0429 | -0.9005 | 81.50 | 75.60 | 0.1195 | -2.77 | 0.6755 | 1.12 | 0.2906 | -- | 3.66 | 5.82 | 102.11 | -54.07 | -11.91 | -- |
| RPG Life Sciences Limited | 6.53bn | 1.83bn | 39.71bn | 1.27k | 21.67 | 7.49 | 19.40 | 6.08 | 110.79 | 110.79 | 395.10 | 320.77 | 1.12 | 2.21 | 9.62 | -- | 31.30 | 21.05 | 39.84 | 27.78 | 67.25 | 63.28 | 28.04 | 16.68 | 3.11 | 222.94 | 0.00 | 24.92 | 12.26 | 11.71 | 109.03 | 44.58 | 27.39 | 37.97 |
| Aarti Drugs Ltd | 23.87bn | 1.68bn | 41.36bn | 1.06k | 24.64 | 3.02 | 18.48 | 1.73 | 18.39 | 18.39 | 260.98 | 149.99 | 0.9535 | 3.22 | 3.28 | -- | 6.71 | 9.09 | 9.96 | 14.39 | 35.40 | 24.67 | 7.04 | 8.08 | 1.03 | 6.45 | 0.31 | -- | -5.60 | 5.74 | -1.90 | 3.53 | 29.85 | -- |
| Unichem Laboratories Ltd | 20.29bn | 1.51bn | 41.67bn | 3.19k | 27.76 | 1.70 | 15.57 | 2.05 | 21.32 | 21.32 | 287.28 | 348.07 | 0.6022 | 0.93 | 2.92 | -- | 4.47 | -0.4194 | 5.98 | -0.5223 | 61.01 | 56.97 | 7.42 | -0.8846 | 1.05 | 7.28 | 0.158 | -- | 23.82 | 13.85 | 295.13 | -- | -18.68 | -- |
| Hikal Ltd | 18.60bn | 908.00m | 44.75bn | 2.06k | 34.11 | 3.55 | 19.87 | 2.41 | 10.64 | 10.64 | 169.08 | 102.38 | 0.7415 | 2.62 | 3.47 | -- | 3.62 | 4.78 | 5.23 | 7.00 | 54.98 | 48.41 | 4.88 | 5.71 | 0.8371 | 2.58 | 0.3773 | 17.14 | 4.21 | 4.29 | 30.46 | 1.46 | -2.77 | 3.13 |
| SeQuent Scientific Ltd | 15.51bn | 218.80m | 47.50bn | 1.20k | 223.59 | 6.75 | 48.12 | 3.06 | 0.85 | 0.85 | 59.96 | 28.15 | 0.9874 | 2.22 | 4.44 | -- | 2.05 | 0.4014 | 3.42 | 0.6553 | 47.67 | 42.75 | 2.08 | 0.42 | 0.9655 | 1.60 | 0.3845 | -- | 13.26 | 5.64 | 161.00 | -20.73 | -0.8147 | -- |
| Innova Captab Ltd | 12.44bn | 1.28bn | 49.19bn | -- | 38.36 | 5.13 | 32.14 | 3.96 | 22.41 | 22.41 | 217.31 | 167.66 | 0.8573 | 4.63 | 4.01 | -- | 8.84 | 10.02 | 11.24 | 15.00 | 34.54 | 28.04 | 10.31 | 8.72 | 1.38 | 67.10 | 0.2606 | -- | 15.02 | 27.21 | 35.95 | 35.69 | 109.94 | -- |
Data as of Jun 30 2025. Currency figures normalised to Dishman Carbogen Amcis Ltd's reporting currency: Indian Rupee INR
5.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HBM Partners AG (Investment Management)as of 31 Dec 2024 | 5.56m | 3.55% |
| Dimensional Fund Advisors LPas of 05 Jun 2025 | 1.49m | 0.95% |
| HSBC Asset Management (India) Pvt Ltd.as of 31 May 2025 | 1.48m | 0.94% |
| SSgA Funds Management, Inc.as of 05 Jun 2025 | 248.22k | 0.16% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 May 2025 | 201.15k | 0.13% |
| American Century Investment Management, Inc.as of 05 Jun 2025 | 167.46k | 0.11% |
| Connor, Clark & Lunn Investment Management Ltd.as of 31 Dec 2023 | 110.03k | 0.07% |
| Dimensional Fund Advisors Ltd.as of 05 Jun 2025 | 78.74k | 0.05% |
| DFA Australia Ltd.as of 30 Apr 2025 | 13.43k | 0.01% |
| Bandhan AMC Ltd.as of 31 May 2025 | 1.05k | 0.00% |
More ▼
Data from 31 Mar 2025 - 15 Jun 2025Source: FactSet Research Systems Inc.
